Package Insert: Information for the User
Rizatriptan Viso Pharmaceutical 10 mg Tablets EFG
Read this package insert carefully before starting to take this medication, as it contains important information for you.
Rizatriptan Viso Farmacéutica belongs to a type of medication called selective agonists of 5-HT1B/1Dreceptors.
RizatriptanViso Farmacéuticais used to treat headache crises of migraine in adults.
Treatment with RizatriptanViso Farmacéutica:
Reduces the swelling of blood vessels surrounding the brain. This swelling causes the headache of a migraine crisis.
Do not take Rizatriptan Viso Farmacéutica:
If you are unsure if any of the above applies to you, talk to your doctor or pharmacist before taking Rizatriptan Viso Farmacéutica.
Warnings and Precautions
Consult your doctor or pharmacist before starting to take Rizatriptan Viso Farmacéutica:
If you take Rizatriptan Viso Farmacéutica frequently, this may cause you to develop chronic headache. In such cases, you should contact your doctor, as you may need to stop taking Rizatriptan Viso Farmacéutica.
Inform your doctor or pharmacist of all your symptoms. Your doctor will decide if you have migraines. You should only take Rizatriptan Viso Farmacéutica for a migraine attack. Rizatriptan Viso Farmacéutica should not be used to treat other headaches that may be caused by more serious diseases.
Inform your doctor or pharmacist that you are using, have used recently, or may need to use any other medication, including those purchased without a prescription.These include herbal medicines and those medications you take regularly for your migraine.This is because Rizatriptan Viso Farmacéutica may affect the way some medications work.Other medications may also affect Rizatriptan Viso Farmacéutica.
Children and Adolescents
There is no experience with the use of Rizatriptan Viso Farmacéutica in children and adolescents under 18 years of age, therefore, the use of Rizatriptan Viso Farmacéutica in children and adolescents under 18 years is not recommended.
Use in Patients Over 65 Years
There are no complete studies that evaluate the safety and efficacy of Rizatriptan Viso Farmacéutica in patients over 65 years of age.
Use of Rizatriptan Viso Farmacéutica with Other Medications
Do not take Rizatriptan Viso Farmacéutica if:
When taking the above-mentioned medications with Rizatriptan Viso Farmacéutica, the risk of adverse effects may increase.
After taking Rizatriptan Viso Farmacéutica, wait at least 6 hours before taking ergotamine-type medications such as ergotamine, dihydroergotamine, or methysergide.
After taking ergotamine-type medications, wait at least 24 hours before taking Rizatriptan Viso Farmacéutica.
Ask your doctor for instructions on how to take Rizatriptan Viso Farmacéutica and information on the risks if:
Use of Rizatriptan Viso Farmacéutica with Food and Beverages
Rizatriptan Viso Farmacéutica may take longer to take effect if taken after meals. Although it is better to take it on an empty stomach, you can take it even if you have eaten.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
The available data on the safety of rizatriptan when used during the first three months of pregnancy do not indicate an increased risk of birth defects.The safety of Rizatriptan Viso Farmacéutica for the fetus when taken by a pregnant woman after the first three months of pregnancy is unknown.
If you are breastfeeding, you can postpone breastfeeding for 12 hours after treatment to avoid exposing your baby.
Driving and Operating Machinery
When taking Rizatriptan Viso Farmacéutica, you may feel drowsiness or dizziness. If this occurs, do not drive or use tools or machines.
Rizatriptan Viso Farmacéutica Contains Aspartame (E951)
This medication may be harmful to people with phenylketonuria because it contains aspartame, which is a source of phenylalanine.
RizatriptanViso Farmacéuticais used to treat migraine attacks. Take RizatriptanViso Farmacéuticaas soon as possible once your migraine headache has started. Do not use it to prevent an attack.
Follow exactly the administration instructions of this medication as indicated by your doctor.If in doubt, consult your doctor or pharmacist again.
RizatriptanViso Farmacéuticatablets should be taken orally and swallowed whole with a liquid.
The recommended dose is 10 mg.
If you are currently taking propanolol or have kidney or liver problems, you should take a lower dose of rizatriptan. You should wait at least 2 hours between taking propanolol and Rizatriptan Viso Farmacéutica, up to a maximum of 2 doses in a 24-hour period.
If the migraine reappears in 24 hours
In some patients, migraine symptoms may reappear within a 24-hour period. If your migraine reappears, you may take an additional dose of Rizatriptan Viso Farmacéutica. You should always wait at least 2 hours between doses.
If after 2 hours you still have a migraine
If you do not respond to the first dose of RizatriptanViso Farmacéuticaduring an attack, you should not take a second dose of RizatriptanViso Farmacéuticafor the same attack. However, you are still likely to respond to RizatriptanViso Farmacéuticaduring the next attack.
Do not take more than 2 doses of Rizatriptan Viso Farmacéutica in a 24-hour period (for example, do not take more than 2 doses of 10 mg in a 24-hour period. You should always wait at least 2 hours between doses).
If your condition worsens, seek medical attention.
Rizatriptan benzoate is also available in buccal tablets that dissolve in the mouth. The buccal tablets can be used when liquids are not available, or to avoid nausea or vomiting that may accompany the ingestion of tablets with liquids.
If you take more Rizatriptan Viso Farmacéutica than you should
If you take more Rizatriptan Viso Farmacéuticathan you should, consult your doctor or pharmacist immediately, or call the Toxicological Information Service, phone 91 5620420, indicating the medication and the amount taken. It is recommended to bring the packaging and the medication leaflet to the healthcare professional.
The signs of overdose may include dizziness, numbness, vomiting, fainting, and slow heart rate.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them. This medicine may cause the following side effects.
In adult studies, the side effects reported most frequently were dizziness, drowsiness, and fatigue.
Frequent (affects between 1 and 10 in 100 patients)
Less frequent (affects between 1 and 10 in 1000 patients)
Rare (affects between 1 and 10 in 10,000 patients)
Unknown frequency
Inform your doctor immediately if you experience symptoms of an allergic reaction, serotonin syndrome, heart attack, or stroke.
Also, inform your doctor if you experience any symptoms that suggest an allergic reaction (such as rash or urticaria) after taking Rizatriptan Viso Farmacéutica.
Reporting side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of sight and reach.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through drains or trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Rizatriptan Viso Pharmaceutical
One 10 mg tablet contains 10 mg of rizatriptan as 14.53 mg of rizatriptan benzoate.
Appearance of the product and packaging contents
The 10 mg tablets are white or off-white, approximately 9 mm in diameter, round, flat, beveled edge, and uncoated, with "468" engraved on one side and nothing on the other.
The tablets are presented in aluminum blisters.
10 mg packaging sizes: 3, 6, 12, or 18 tablets.
Only some packaging sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
Glenmark Arzneimittel GmbH
Industriestr. 31
82194 Gröbenzell
Germany
Responsible manufacturer
Glenmark Pharmaceuticals Europe Limited
Building 2, Croxley Green Business Park,Croxley Green
Hertfordshire, WD18 8YA
United Kingdom
or
Glenmark Pharmaceuticals s.r.o.
Fibíchova 143
566 17 Vysoké Mýto
Czech Republic
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Viso Farmacéutica, S.L.U.
c/ Retama 7, 7th Floor
28045 Madrid
Spain
This medication is authorized in the European Economic Area member states with the following names:
Germany | Rizatriptan Glenmark 10mg Tabletten |
Denmark | Rizatriptan Glenmark |
France | Rizatriptan Glenmark 10mg comprimés |
Italy | RIZATRIPTANO GLENMARK 10mg compressa |
Netherlands | Rizatriptan Glenmark 10mg Tabletten |
Norway | Rizatriptan Glenmark |
Spain | Rizatriptan Viso Farmacéutica 10mg comprimidos EFG |
Sweden | Rizatriptan Glenmark |
United Kingdom | Rizatriptan 10mg Tablets |
Last review date of this leaflet:July 2024.
More detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.